Malignant peritoneal mesothelioma

Area of Science:

• Oncology
• Surgical Oncology
• Medical Oncology

Background:

• Peritoneal malignant mesothelioma is rare, with limited systemic chemotherapy options and poor response rates.
• Malignant ascites and bowel obstruction are common, significantly impacting patient morbidity and mortality.
• Current imaging techniques often understage peritoneal disease, complicating treatment planning.

Purpose of the Study:

• To evaluate the author's approach using cytoreductive surgery combined with intraperitoneal hyperthermic chemotherapy (CS-IPHC) for peritoneal malignant mesothelioma.
• To assess the efficacy of CS-IPHC in managing symptoms, ascites, and obstruction.
• To determine the safety and survival outcomes associated with this combined treatment modality.

Main Methods:

• Surgical staging for accurate disease assessment.
• Tumor debulking, and surgical management of bowel obstruction.
• Intraoperative hyperthermic chemotherapy perfusion (IPHC) following cytoreductive surgery (CS).

Main Results:

• Rapid clinical symptom improvement and durable resolution of malignant ascites.
• Acceptable morbidity and mortality rates associated with the CS-IPHC procedure.
• A median survival of approximately 27 months was observed in treated patients.

Conclusions:

• CS-IPHC is an effective approach for peritoneal malignant mesothelioma, addressing staging, debulking, and ascites.
• The procedure offers significant symptom relief and improved survival compared to conventional chemotherapy.
• Further research is needed to develop effective systemic therapies to consolidate treatment gains.